Reaktionsgleichung
C1(CCCN2CCN(C3C=C(F)C(OC)=CC=3F)CC2)CCCCC1.[C:26]([C:30]1[CH:35]=[CH:34][C:33]([C:36](=[O:56])[CH2:37][CH2:38][CH2:39][N:40]2[CH2:45][CH2:44][N:43]([C:46]3[CH:51]=[C:50]([F:52])[C:49]([O:53]C)=[CH:48][C:47]=3[F:55])[CH2:42][CH2:41]2)=[CH:32][CH:31]=1)([CH3:29])([CH3:28])[CH3:27]>>[C:26]([C:30]1[CH:35]=[CH:34][C:33]([C:36](=[O:56])[CH2:37][CH2:38][CH2:39][N:40]2[CH2:45][CH2:44][N:43]([C:46]3[CH:51]=[C:50]([F:52])[C:49]([OH:53])=[CH:48][C:47]=3[F:55])[CH2:42][CH2:41]2)=[CH:32][CH:31]=1)([CH3:29])([CH3:27])[CH3:28]Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
Production Example 94 was repeated except that 1-(3-cyclohexylpropyl)-4-(2,5-difluoro-4-methoxyphenyl)piperazine was replaced with 1-(4-tert-butylphenyl)-4-[4-(2,5-difluoro-4-methoxyphenyl)piperazin-1-yl]butan-1-one (330 mg). The resulting crude product was purified on TLC (developer, ethyl acetate: hexane=2:1) to provide 1-(4-tert-butylphenyl)-4-[4-(2,5-difluoro-4-hydroxyphenyl)piperazin-1-yl]butan-1-one (146 mg).
Aufarbeitung
- customThe resulting crude product was purified on TLC (developer, ethyl acetate: hexane=2:1)
Quellen und Nachweise
- ORD-Eintrag
- ord-04100dbdd2e84cd0b5b8eed414d74221
- Quelldatensatz
- uspto-grants-2008_11
- Patentnummer
- US07449466B2
Verknüpfte Notizen
Wird geladen…